Key Insights

Highlights

Success Rate

64% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 77/100

Termination Rate

23.8%

5 terminated out of 21 trials

Success Rate

64.3%

-22.2% vs benchmark

Late-Stage Pipeline

19%

4 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed with results

Key Signals

3 with results64% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (2)
P 1 (3)
P 2 (10)
P 3 (4)

Trial Status

Completed9
Terminated5
Unknown3
Recruiting2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

64.3%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07242547Phase 2Recruiting

Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

NCT07476287Phase 2Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT04985357Withdrawn

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

NCT05566041Phase 3Active Not RecruitingPrimary

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

NCT01306045Phase 2Completed

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

NCT04622228Phase 2CompletedPrimary

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

NCT03699956Phase 3TerminatedPrimary

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

NCT03083691Phase 2Completed

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

NCT04253145Phase 1UnknownPrimary

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

NCT04308785Phase 2TerminatedPrimary

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

NCT00637624Not ApplicableTerminated

N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

NCT00263731Completed

Metabolomic Analysis of Lung Cancer

NCT02936323Phase 1Completed

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

NCT03871205Phase 1Unknown

Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer

NCT00265200Phase 2Terminated

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

NCT02736916Not ApplicableUnknownPrimary

HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer

NCT00270166Phase 3Completed

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

NCT00294931Phase 2CompletedPrimary

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT00308529Phase 2CompletedPrimary

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

NCT00037713Phase 3CompletedPrimary

Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG

Scroll to load more

Research Network

Activity Timeline